BERN

Justin Smith

Q: How accurate are Justin Smith's stock ratings?

About 61% of Justin's ratings were profitable over a one-year hold, with an average return of +5.5% per rating, measured by 13Foresight from historical prices.

Q: How is Justin ranked?

Justin Smith is ranked #1220 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Bernstein

Wall Street Analyst

★★★☆☆

#1220

on 13Foresight · ranked by our own returns

61%

Success Rate

+5.5%

Average Return

23 of 38 calls profitable · -4.7% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 61% of Justin Smith's ratings turned a profit when each position was held for 1 year — averaging +5.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

46 Buy 6 Hold 6 Sell

Justin's Stock Coverage 25 ratings · 2026-08-10

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
DE:MRK Merck KGaA	Aug 07, 2026	HOLD	Buy -4.8% avg upside 33 analysts	$151.00 5.19% Upside	·	·
GB:0QIU Novo Nordisk	Aug 05, 2026	SELL	Hold +35.0% avg upside 29 analysts	$200.00 34.42% Downside	·	·
FR:SAN Sanofi	Aug 04, 2026	BUY	Strong Buy +30.1% avg upside 30 analysts	$106.21 41.02% Upside	-0.3%	·
GB:GSK GlaxoSmithKline	Aug 03, 2026	BUY	Hold -0.8% avg upside 25 analysts	$3010.00 53.50% Upside	+1.1%	·
GB:AZN AstraZeneca	Jul 29, 2026	BUY	Strong Buy +22.1% avg upside 26 analysts	$20200.00 69.84% Upside	-6.8%	·
GB:0QW0 arGEN X	Jul 28, 2026	BUY	Strong Buy -20.8% avg upside 24 analysts	$986.00 27.60% Upside	·	·
CH:ROP Roche Holding AG	Jul 27, 2026	BUY	Buy -9.1% avg upside 23 analysts	$434.50 18.36% Upside	-0.9%	·
CH:LONN Lonza Group Ltd	Jul 24, 2026	BUY	Strong Buy +12.7% avg upside 21 analysts	—	+1.3%	·
CH:NOVN Novartis AG	Jul 22, 2026	HOLD	Buy -12.0% avg upside 32 analysts	$133.00 5.54% Upside	-1.9%	·
NVS Novartis	Mar 19, 2026	HOLD	Hold -14.5% avg upside 24 analysts	—	+5.5%	·
GB:0MGB Genmab A/S	Feb 23, 2026	SELL	Buy +4.7% avg upside 23 analysts	$1400.00 29.91% Downside	·	·
GMAB Genmab	Sep 08, 2025	SELL	Buy +15.3% avg upside 27 analysts	—	-13.5%	·
PFE Pfizer	Aug 17, 2025	HOLD	Buy +24.7% avg upside 45 analysts	—	+15.5%	·
FR:EAPI Euroapi SA	Mar 31, 2025	HOLD	Hold +699.5% avg upside 5 analysts	$2.90 187.11% Upside	-53.5%	·
ES:GRF Grifols	Dec 10, 2024	BUY	Buy +45.4% avg upside 12 analysts	$21.50 111.37% Upside	+22.5%	·
MRK Merck & Company	Mar 11, 2024	SELL	Strong Buy +0.2% avg upside 43 analysts	$104.00 19.21% Downside	+20.7%	·
BMY Bristol-Myers Squibb	Mar 11, 2024	HOLD	Buy -5.8% avg upside 42 analysts	$51.00 21.28% Downside	+18.8%	·
DE:FME Fresenius Medical Care AG & Co. KGaA	Nov 17, 2023	BUY	Hold +19.6% avg upside 23 analysts	$71.00 68.84% Upside	+20.3%	·
DE:FRE Fresenius SE & Co. KGaA	Nov 17, 2023	BUY	Strong Buy +8.7% avg upside 20 analysts	$70.00 48.74% Upside	+19.8%	·
RHHBY Roche Holding	Feb 27, 2023	BUY	Strong Buy +102.0% avg upside 14 analysts	—	-6.8%	·
ABBV AbbVie	Nov 08, 2022	HOLD	Strong Buy -3.1% avg upside 46 analysts	$140.00 43.06% Downside	-0.5%	·
GSK GlaxoSmithKline	Sep 03, 2019	BUY	Hold -17.4% avg upside 19 analysts	—	-3.5%	·
FSNUY Fresenius SE & Co	Nov 12, 2018	BUY	Strong Buy -22.6% avg upside 7 analysts	—	-7.8%	·
FMS Fresenius Medical Care	Feb 24, 2017	HOLD	Hold +68.4% avg upside 15 analysts	—	+33.9%	·
LLY Eli Lilly & Co	Apr 07, 2016	HOLD	Strong Buy -12.3% avg upside 48 analysts	$78.00 93.34% Downside	+17.4%	·

🔒 20 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Justin Smith — Frequently Asked Questions

How accurate are Justin Smith's stock ratings?

Based on the calls 13Foresight could measure, about 61% of Justin's ratings were profitable over a one-year hold, with an average return of +5.5% per rating, or -4.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Justin ranked on 13Foresight?

Justin Smith is currently ranked #1220 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Justin cover?

Justin most recently has ratings on DE:MRK, GB:0QIU, FR:SAN, GB:GSK, GB:AZN, GB:0QW0, CH:ROP, CH:LONN, CH:NOVN, NVS, GB:0MGB, GMAB and 13 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Justin Smith

Rating Distribution

Welcome to 13Foresight!